JP2024546026A5 - - Google Patents

Info

Publication number
JP2024546026A5
JP2024546026A5 JP2024527503A JP2024527503A JP2024546026A5 JP 2024546026 A5 JP2024546026 A5 JP 2024546026A5 JP 2024527503 A JP2024527503 A JP 2024527503A JP 2024527503 A JP2024527503 A JP 2024527503A JP 2024546026 A5 JP2024546026 A5 JP 2024546026A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
ala
approximately
ile
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024527503A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024546026A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/131375 external-priority patent/WO2023083301A1/zh
Publication of JP2024546026A publication Critical patent/JP2024546026A/ja
Publication of JP2024546026A5 publication Critical patent/JP2024546026A5/ja
Pending legal-status Critical Current

Links

JP2024527503A 2021-11-12 2022-11-11 Glp-1受容体及びgip受容体二重アゴニストの医薬組成物及びその使用 Pending JP2024546026A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202111341752 2021-11-12
CN202111341752.0 2021-11-12
PCT/CN2022/131375 WO2023083301A1 (zh) 2021-11-12 2022-11-11 Glp-1受体和gip受体双重激动剂的药物组合物及其用途

Publications (2)

Publication Number Publication Date
JP2024546026A JP2024546026A (ja) 2024-12-17
JP2024546026A5 true JP2024546026A5 (cg-RX-API-DMAC7.html) 2025-11-11

Family

ID=86335124

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024527503A Pending JP2024546026A (ja) 2021-11-12 2022-11-11 Glp-1受容体及びgip受容体二重アゴニストの医薬組成物及びその使用

Country Status (10)

Country Link
US (1) US20250115654A1 (cg-RX-API-DMAC7.html)
EP (1) EP4431522A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024546026A (cg-RX-API-DMAC7.html)
KR (1) KR20240109258A (cg-RX-API-DMAC7.html)
CN (1) CN118103391A (cg-RX-API-DMAC7.html)
AU (1) AU2022386489A1 (cg-RX-API-DMAC7.html)
CA (1) CA3237796A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024005663A (cg-RX-API-DMAC7.html)
TW (1) TW202333773A (cg-RX-API-DMAC7.html)
WO (1) WO2023083301A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116693652B (zh) * 2023-08-02 2024-01-05 北京惠之衡生物科技有限公司 一种glp-1/gip受体双重激动剂衍生物及其制备方法和应用
WO2025124473A1 (zh) 2023-12-12 2025-06-19 江苏恒瑞医药股份有限公司 Glp-1类似物治疗代谢疾病的方法及医药用途
WO2025149039A1 (zh) * 2024-01-12 2025-07-17 杭州中美华东制药有限公司 长效glp-1/gip双激动剂的药物组合物
WO2025252197A1 (zh) * 2024-06-07 2025-12-11 江苏恒瑞医药股份有限公司 药物组合物
TW202611066A (zh) * 2024-08-16 2026-03-16 大陸商江蘇恆瑞醫藥股份有限公司 Glp-1類似物的醫藥用途
WO2026092429A1 (zh) * 2024-10-28 2026-05-07 江苏恒瑞医药股份有限公司 药物递送组合物
WO2026153399A1 (zh) * 2025-01-15 2026-07-23 江苏恒瑞医药股份有限公司 一种药物组合物
WO2026153411A1 (zh) * 2025-01-20 2026-07-23 江苏豪森药业集团有限公司 一种双重激动剂的药物组合物、制备方法及其医药用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101987868B (zh) * 2009-07-30 2013-09-04 江苏豪森医药集团有限公司 Glp-1类似物的衍生物或其可药用盐和用途
RU2013133803A (ru) * 2010-12-22 2015-01-27 Маркадиа Байотек, Инк. Способы лечения метаболических нарушений и ожирения при помощи пептидов на основе глюкагона, активных по отношению к рецепторам гип и гпп
KR102002783B1 (ko) * 2011-06-10 2019-07-24 베이징 한미 파마슈티컬 컴퍼니 리미티드 포도당 의존성 인슐리노트로핀 폴리펩타이드 유사물질, 이의 약학적 조성물 및 응용
CA2872314C (en) * 2012-05-03 2021-08-31 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
HUE035803T2 (en) * 2012-12-21 2018-05-28 Sanofi Sa Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists
JP7250706B2 (ja) * 2017-06-21 2023-04-03 アムジエン・インコーポレーテツド 胃抑制ペプチド受容体(gipr)に対するアンタゴニスト結合タンパク質/glp-1受容体アゴニスト融合タンパク質を使用した代謝障害の治療又は寛解方法
MY206306A (en) * 2018-10-26 2024-12-07 Novo Nordisk As Stable semaglutide compositions and uses thereof
AU2020256648B2 (en) * 2019-04-11 2026-01-15 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Multi-receptor agonist and medical use thereof
WO2021053578A1 (en) * 2019-09-19 2021-03-25 Dr. Reddy’S Laboratories Limited Improved purification processes for liraglutide
AU2020418207A1 (en) * 2019-12-30 2022-08-25 Gan & Lee Pharmaceuticals Co., Ltd. Long-acting GLP-1 compound
CN118754965A (zh) * 2020-05-29 2024-10-11 北京拓界生物医药科技有限公司 Glp-1和gip受体双重激动剂化合物及其应用

Similar Documents

Publication Publication Date Title
JP7461997B2 (ja) 制御放出および持続的放出のためのelp融合タンパク質
US7939494B2 (en) Method for administering GLP-1 molecules
WO2021136296A1 (zh) 胰岛素衍生物
JP2024170428A (ja) グルカゴン様ペプチド1(glp1)-増殖分化因子15(gdf15)融合タンパク質及びその使用
JP2006520818A (ja) ポリエチレングリコール結合glp−1化合物
JP2023526973A5 (cg-RX-API-DMAC7.html)
CA2708762A1 (en) Formulation of insulinotropic peptide conjugates
JP2006520818A5 (cg-RX-API-DMAC7.html)
JP2024546026A (ja) Glp-1受容体及びgip受容体二重アゴニストの医薬組成物及びその使用
JP2011506442A5 (cg-RX-API-DMAC7.html)
WO2011109784A1 (en) Formulation of insulinotropic peptide conjugates
WO2011109787A1 (en) Methods of administering insulinotropic peptides
US12551541B2 (en) Albumin bound macromolecule tri-agonist activating GLP 1/GIP/glucagon receptors and methods therefor
WO2023143458A1 (zh) 酰化胰岛素
CN119386161A (zh) 用fgf21变体治疗代谢障碍的方法
TW202227123A (zh) 一種包含人白細胞介素2變體或其衍生物的醫藥組成物及其用途
WO2025185605A1 (en) Polypeptide conjugates and methods of uses
EA053272B1 (ru) Фармацевтическая композиция двойного агониста рецептора glp-1 и рецептора gip и ее применение
HK1166449B (en) Method for administering glp-1 molecules